Daniel M.F. Claassens
- Internal Medicine top 5%
- Venous Thromboembolism Diagnosis and Management 8
-
- Antiplatelet Therapy and Cardiovascular Diseases 15
- Acute Myocardial Infarction Research 9
- Cardiac Valve Diseases and Treatments 1
- Pharmacology top 10%
-
- Coronary Interventions and Diagnostics 8
- Lipoproteins and Cardiovascular Health 3
-
- Cardiac Imaging and Diagnostics 1
-
- Blood Coagulation and Thrombosis Mechanisms 1
- Co-authors
- Jurriën M. ten BergFolkert W. AsselbergsThomas O. BergmeijerPaul W.A. JanssenGerrit J.A. VosVera H.M. DeneerWillem J.M. DewildeArnoud W.J. van ‘t Hof
- Journals
- Journal of Clinical Medicine (2 papers)Drug Metabolism and Personalized Therapy (2 papers)Pharmacogenomics (1 paper)
- Partner nations
- NetherlandsUnited KingdomSaudi Arabia
In The Last Decade
Daniel M.F. Claassens
15 papers receiving 507 citations
Hit Papers
Peers
Comparison fields: 5 of 45
- Internal Medicine 118
- Cardiology and Cardiovascular Medicine 442
- Pharmacology 67
- Surgery 237
- Endocrinology, Diabetes and Metabolism 75
Countries citing papers authored by Daniel M.F. Claassens
This map shows the geographic impact of Daniel M.F. Claassens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel M.F. Claassens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel M.F. Claassens more than expected).
Fields of papers citing papers by Daniel M.F. Claassens
This network shows the impact of papers produced by Daniel M.F. Claassens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel M.F. Claassens. The network helps show where Daniel M.F. Claassens may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Daniel M.F. Claassens, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 27 | |
| 2 | 2022 | 2 | |
| 3 | 2021 | 4 | |
| 4 | 2021 | 2 | |
| 5 | 2021 | 17 | |
| 6 | 2021 | 6 | |
| 7 | 2021 | 16 | |
| 8 | 2021 | 14 | |
| 9 | 2021 | 2 | |
| 10 | 2020 | 8 | |
| 11 | 2020 | 6 | |
| 12 | 2020 | 10 | |
| 13 | A Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCIbreakdown → | 2019 | 378 |
| 14 | 2019 | 0 | |
| 15 | 2018 | 20 | |
| 16 | 2017 | 5 |
About Daniel M.F. Claassens
Daniel M.F. Claassens is a scholar working on Internal Medicine, Cardiology and Cardiovascular Medicine and Surgery, having authored 16 papers that have together received 517 indexed citations. Recurring topics across this work include Antiplatelet Therapy and Cardiovascular Diseases (15 papers), Acute Myocardial Infarction Research (9 papers), Venous Thromboembolism Diagnosis and Management (8 papers), Coronary Interventions and Diagnostics (8 papers), Lipoproteins and Cardiovascular Health (3 papers), Cardiac Imaging and Diagnostics (1 paper), Cardiac Valve Diseases and Treatments (1 paper) and Blood Coagulation and Thrombosis Mechanisms (1 paper). The work is most often cited by research in Internal Medicine (118 citations), Cardiology and Cardiovascular Medicine (442 citations) and Pharmacology (67 citations). Daniel M.F. Claassens has collaborated with scholars based in Netherlands, United Kingdom and Saudi Arabia. Frequent co-authors include Jurriën M. ten Berg, Folkert W. Asselbergs, Thomas O. Bergmeijer, Paul W.A. Janssen, Gerrit J.A. Vos, Vera H.M. Deneer, Willem J.M. Dewilde, Arnoud W.J. van ‘t Hof, Jean‐Paul R. Herrman and Emanuele Barbato. Their work appears in journals such as Journal of Clinical Medicine, Drug Metabolism and Personalized Therapy, Pharmacogenomics, Circulation Cardiovascular Interventions and American Journal of Cardiovascular Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.